

HK Kong E and Ca n L and e o E and eo HK Kong L da eno e on o e
on o a no n e a , a eno e e a on a o a a a o o e e and e e d a a n
a a o e e o a n o o o e e a n o o n e a n e on e o e o a n a o e on o
a n o n e a .



上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(on o a d o a n n o o a d n e o e' R e a o C n a d a)
(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

T... R.I 13.09(2) R.I 13.10B R.I G...
L... S... T S E H K L... I I...
Pr... rPr I A S... F... Or... (C... r 571 L H
K...).

T... r 2013 S... F... P... I (Gr...) C...
L.* ("Company", r... b... ll... "Group"). T... l r...
r... r... r... PRC A... S... r B... E r r...
b... .

B Or r B...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Ca an

S... P... R... bl... C...
30 O b r 2013

A a e d e o a n n o n e a , e e e a e d e o a e . C a g and . a o E n ; e n o n - e e a e
d e o a e . G o G a n a n , . a n e n n , . a n G o a , . a n n a n a n d . K u n ; a n d
e n d e a d a n o n - e e a e d e o a e . H n J o n , D . a n e o n , . L a n - A d a n D d a n d .
C o H n .

* F o d a a o n o e o n

Assets

Unit: RMB

Items	The Reporting Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period	Description
Goodwill	10,251,236.77	596,825,644.44	
Intangible assets	2,878,850.90	13,168,079.40	
Investments in subsidiaries	80,220,837.82	218,571,999.35	Investment in subsidiaries
Other non-current assets	462,524.66	-1,915,596.10	
Equity	-23,279,225.73	-195,412,839.05	
Liabilities	-7,678,145.29	-13,090,843.51	
Total	62,856,079.13	618,146,444.53	

2.2 Top 10 shareholders of the Company as of September 30, 2015

Unit: Shares

The shareholding status of the Top 10 shareholders					
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen
Singapore Financial Trust (Group) Limited	Direct	41.09	920,641,314	0	N
HKSCC NOMINEES LIMITED (sole)	Ordinary	14.96	335,255,500	0	
China Life Insurance Company Limited - Domestic Policy Department - 005L - FH002 Subsidiary		1.69	37,868,964	0	N
China Construction Bank - Huaihai Branch Shanghai		1.44	32,188,808	0	N
Industrial Commercial Bank of China - Huaihai Branch Shanghai		0.95	21,318,308	0	N
Industrial Commercial Bank of China - Jiangsu Branch Shanghai		0.85	19,120,000	0	N
China Merchants Bank Limited - Eastern Branch of Shanghai		0.81	18,110,252	0	N
National Social Security Fund 104		0.74	16,599,805	0	N
Bank of China - Pacific Branch of Shanghai		0.46	10,199,839	0	N
Bank of China - Asia Branch of Shanghai		0.45	10,000,000	0	N

The Top 10 unrestricted shareholders of tradable shares

Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
S... F... H... T... l... (Gr...) C... , L...	920,641,314	RMB r... r... r
HKSCC NOMINEES LIMITED (note)	335,255,500	O r... l... r... r
C... L... I... r... C... , L... — D... — P r... I D... — 005L — FH002 S...	37,868,964	RMB r... r... r
C... C... r... B... — H... A... H... L... S... S... r... I... m... F...	32,188,808	RMB r... r... r
I... r... l... C... m... r... l... B... C... — H... T... F... C... L... F... , S... S... r... I... m... F...	21,318,308	RMB r... r... r
I... r... l... C... m... r... l... B... C... — J... S... , G r... , I... l... b... -... S... S... r... I... m... F...	19,120,000	RMB r... r... r
C... M... r... B... C... , L... — E... r... B... B... D... S... r... r... A... l... , S... S... r... I... m... F...	18,110,252	RMB r... r... r
N... I... S... I... S... r... F... 104... r... l...	16,599,805	RMB r... r... r
B... C... m... r... — P... H... C... 50 Q... - S... r... I... m... F...	10,199,839	RMB r... r... r
B... C... m... r... — A... S... , S... r... I... m... F...	10,000,000	RMB r... r... r
<p align="center">D... r... , S... r... l... r... l... r... r... r... , b... r... l... r</p>	<p>T... r... I... r... l... C... m... r... l... B... C... — H... T... F... C... L... F... , S... S... r... I... m... F... I... r... l... C... m... r... l... B... C... — J... S... , G r... , I... l... l... b... -... S... S... r... I... m... F... r... b... I... r... l... C... m... r... l... B... C... L... ; T... r... B... C... m... r... — P... H... C... 50 Q... - S... r... I... m... F... F... B... C... m... r... — A... S... r... r... r... r... b... B... C... m... r... C... , L... ; T... r... m... r... C... C... r... B... — H... A... H... L... S... S... r... I... m... F... B... C... m... r... — A... S... , S... r... m... r... r... b... H... A... F... M... m... C... , L... ; T... r... r... N... I... S... I... S... r... F... 104... r... l... B... C... m... r... — P... H... C... 50 Q... - S... r... I... m... F... r... b... P... , F... M... m... C... , L... ; T...</p>	

§3 SIGNIFICANT EVENTS

3.1 Significant events during the reporting period

Affecting Assets Affecting Liabilities

Unit: RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Current assets	2,485,783,000.50	4,972,524,758.70	-50%	Mainly due to the decrease in cash and bank deposits in 2013.
Intangible assets	1,316,781,579.78	907,307,576.06	45%	Mainly due to the increase in goodwill in 2013.
Investments	7,615,057.77	17,674,707.55	-57%	Mainly due to the decrease in long-term equity investments in 2013.
Property, plant and equipment	2,368,367,750.12	1,752,799,860.87	35%	Mainly due to the increase in property, plant and equipment in 2013.
Development expenditures	42,946,124.18	29,475,413.33	46%	Mainly due to the increase in R&D expenditures in 2013.
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Mainly due to the increase in goodwill in 2013.
Other non-current assets	236,069,350.21	100,654,101.39	135%	Mainly due to the increase in other non-current assets in 2013.
Deferred tax assets	72,033,067.63	31,482,514.80	129%	Mainly due to the increase in deferred tax assets in 2013.
Share-based payments	1,199,559,074.08	519,422,250.00	131%	Mainly due to the increase in share-based payments in 2013.
Other non-current liabilities	12,240,519.57	4,725,748.28	159%	Mainly due to the increase in other non-current liabilities in 2013.
Other current liabilities	33,196,473.53	526,384,431.15	-94%	Mainly due to the decrease in other current liabilities in 2013.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. *
(Shanghai) Fosun Pharmaceutical (Group) Co., Ltd. *
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. *

3.3 Fill in the blank: Calculate the value of the following expression.

$$\square \sqrt{A^2 + B^2} = \sqrt{N^2 + A^2 + B^2}$$

3.4 Fill in the blank: Calculate the value of the following expression.

$$\square \sqrt{A^2 + B^2} = \sqrt{N^2 + A^2 + B^2}$$

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal Representative: Chen Qiyu

30 October 2013

Consolidated balance sheet (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-up capital (or share capital)	2,240,462,364.00	2,240,462,364.00
Reserves	4,396,998,107.25	4,287,287,930.01
Loans from shareholders		
Share premium		
Shareholders' loans	1,338,476,598.49	1,338,476,598.49
Goodwill		
Retained earnings	6,621,610,997.36	5,703,028,462.15
Financial liabilities	-4,289,492.31	-10,462,767.38
Total equity attributable to owners (or shareholders)	14,593,258,574.79	13,558,792,587.27
Minority interest	1,889,445,595.04	1,745,855,848.86
Total equity attributable to owners (or shareholders) and minority interest	16,482,704,169.83	15,304,648,436.13
Total liabilities and equity attributable to owners (or shareholders) and minority interest	27,589,580,696.34	25,507,140,466.01

Liabilities
 Current: Current

Current liabilities:
 H... J...

Debt
 Debt: J...

Balance sheet of the Parent Company

30 e e e 2013

Pr o r b : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

: C r r : RMB T

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C	967,810,425.06	2,804,108,583.37
F		
Bll r		
Tr		
Pr		
I r r	112,185,785.22	98,972,778.68
D	24,240,000.00	
O r r	1,207,151,982.57	941,562,545.17
I r	517,042.01	516,409.53
N - r r		
O r r r	280,000,000.00	250,000,000.00
T l r r	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
A l bl - r - l		
H l - r r		
L - r r r		
L - r r	5,471,340,934.74	4,173,763,622.82
I r r r		
F	20,153,012.47	20,815,349.96
C r r r r		
Pr		
D l		
Pr b l l		
O l		
I bl	3,215,662.67	3,496,198.41
D l r r		
G ll		
L - r r r		
D r r		
O r r r	4,470,831,299.40	4,035,133,683.09
T l - r r	9,965,540,909.28	8,233,208,854.28
T l	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
S r - r m l .		
F l l . b l l r r		
B l l b l		
T r b l		
R		
. b l	26,138,331.81	29,108,232.08
T b l	16,833,088.84	5,188,721.77
I r b l	155,509,208.37	152,405,396.96
D b l		
O r b l	554,584,851.12	46,800,203.98
N r r . l . b l r	360,000,000.00	355,000,000.00
O r r r . l . b l		499,375,000.00
T . l r r . l . b l	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
L r m l	125,000,000.00	165,000,000.00
B b l	4,070,832,033.25	4,063,347,254.54
L r m b l		
S b l		
A r l . b l		
D r r m l . b l		
O r r r . l . b l	2,275,000.00	2,500,000.00
T . l r r . l . b l	4,198,107,033.25	4,230,847,254.54
T . l l . b l	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
P l (r r l)	2,240,462,364.00	2,240,462,364.00
C l r r	3,754,014,307.53	3,755,009,519.04
L r r		
S r r		
S r l r r	305,635,420.68	305,635,420.68
G r l r r		
. r r	946,161,538.54	708,537,057.98
T . l r b r . b l r (r r b r . b l r l r)	7,246,273,630.75	7,009,644,361.70
T . l l . b l r b r . b l r (r r b r . b l r l r)	12,557,446,144.14	12,328,369,171.03

L . l R . r
C m : C Q ,

C . F l O r :
H J

D r r A ,
D r m : J

4.2

Consolidated Income Statement

2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Income: Operating revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Interest income				
Exchange income				
Financial income				
II. Total expense	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Income: Operating expense	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Interest expense				
Financial expense				
Provision for doubtful accounts				
Change in fair value of financial assets				
Net gain from disposal of long-term assets				
Provision for bad debts				
Amortization expense				
Business expense	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Selling expense	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Administrative expense	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Financial expense	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Asset impairment loss	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Provision for doubtful accounts (“-” indicates addition)	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Interest income (“-” indicates addition)	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Income: Government income	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Financial income (“-” indicates addition)				
III. Operating profit (“-” indicates addition)	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Provision for doubtful accounts	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Loss: Net loss	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Income: Loss from disposal of long-term assets	260,198.27	-243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

2013

Parent: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Currency: RMB T

Items	Current Amount (Jul - Sep)	Amount of the Last Period (Jul - Sep)	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
I. Operating Profit				
Operating Income				
Operating Expenses				
Selling Expenses				
Administrative Expenses	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Financial Expenses	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Asset Impairment Loss				
Provision for Expected Credit Loss ("ECL")				
Income Tax Expense ("EIT")	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Other Income: Government Subsidies	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating Profit ("EOP")	-34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Provision for Expected Credit Loss	76,900.00	234,093.38	236,049.11	734,093.38
Loss on Disposal of Assets		-570,000.00	2,514,544.42	860,000.00
Income Tax Expense			5,725.77	
III. Total Profit ("EIP")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Income Tax Expense				
IV. Net Profit ("ENP")	-34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Earnings				
(1) Basic Earnings				
(2) Diluted Earnings				
Other Income			51,779.40	27,699,470.25
II. Total Profit	-34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Prepared by: CFO: Director: Director
 Date: CQ, H, J, D, J

Statement of Cash Flow of the Parent Company (Continued)

d u a - e e e 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan - Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan - Sep)
III. Cash flow generated from financing activities:		
C r r r l r b		
C r r r b r r	255,115,078.77	
C r r r b		1,486,950,000.00
O r r r l	1,904,031,173.98	4,295,169,165.49
S b l l r r	2,159,146,252.75	5,782,119,165.49
C r b l r	790,115,078.77	454,000,000.00
C r r b r r r r r r r	674,744,025.09	302,177,196.32
O r r l	2,109,471,293.35	5,478,222,986.00
S b l l r r	3,574,330,397.21	6,234,400,182.32
N l r r r	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
P l O b l r l	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L l R r
C r : C Q r

C F l O r:
H J

D r r A r
D r r : J